7 analysts have expressed a variety of opinions on Hims & Hers Health HIMS over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 1 | 2 | 0 | 1 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 2 | 0 | 1 | 0 | 1 |
| 3M Ago | 1 | 1 | 0 | 0 | 0 |
Analysts have recently evaluated Hims & Hers Health and provided 12-month price targets. The average target is $36.43, accompanied by a high estimate of $60.00 and a low estimate of $24.00. Marking an increase of 27.38%, the current average surpasses the previous average price target of $28.60.
Breaking Down Analyst Ratings: A Detailed Examination
In examining recent analyst actions, we gain insights into how financial experts perceive Hims & Hers Health. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Craig Hettenbach | Morgan Stanley | Raises | Equal-Weight | $60.00 | $42.00 |
| Daniel Grosslight | Citigroup | Raises | Sell | $25.00 | $24.00 |
| David Larsen | BTIG | Announces | Buy | $35.00 | - |
| Korinne Wolfmeyer | Piper Sandler | Raises | Neutral | $24.00 | $21.00 |
| Ryan MacDonald | Needham | Raises | Buy | $31.00 | $28.00 |
| Craig Hettenbach | Morgan Stanley | Announces | Overweight | $42.00 | - |
| Maria Ripps | Canaccord Genuity | Raises | Buy | $38.00 | $28.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Hims & Hers Health. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Hims & Hers Health compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Hims & Hers Health's stock. This analysis reveals shifts in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Hims & Hers Health's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Hims & Hers Health analyst ratings.
Get to Know Hims & Hers Health Better
Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, primary care, and more.
Understanding the Numbers: Hims & Hers Health's Finances
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Hims & Hers Health displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 77.13%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Hims & Hers Health's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 18.82% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Hims & Hers Health's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 18.85% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Hims & Hers Health's ROA excels beyond industry benchmarks, reaching 13.96%. This signifies efficient management of assets and strong financial health.
Debt Management: Hims & Hers Health's debt-to-equity ratio is below the industry average at 0.03, reflecting a lower dependency on debt financing and a more conservative financial approach.
How Are Analyst Ratings Determined?
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
